BIOCRYST PHARMACEUTICALS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
BIOCRYST PHARMACEUTICALS INC. - More news...
BIOCRYST PHARMACEUTICALS INC. - More news...
-
BioCryst Pharmaceuticals, Inc. - BCRX Stock Chart Technical Analysis for 12-10-2019
-
BioCryst Pharmaceuticals, Inc. - BCRX Stock Chart Technical Analysis for 11-29-2019
-
BioCryst Pharmaceuticals, Inc. - BCRX Stock Chart Technical Analysis for 11-25-2019
-
BioCryst Pharmaceuticals,Inc - BCRX Stock Chart Technical Analysis for 11-19-19
-
BioCryst Pharmaceuticals, Inc. - BCRX Stock Chart Technical Analysis for 09-19-2019
-
BioCryst Pharmaceuticals, Inc. - BCRX Stock Chart Technical Analysis for 05-30-2019
-
BioCryst Pharmaceuticals, Inc. - BCRX Stock Chart Technical Analysis for 05-21-2019
- New Research Coverage Highlights Immunomedics, Surmodics, PDF Solutions, Stepan, Express Scripts Holding, and BioCryst Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018
-
BioCryst Pharmaceuticals, Inc. - BCRX Stock Chart Technical Analysis for 08-02-18
- Great Point Partners, LLC Remains Opposed To The BioCryst Pharmaceutical Proposed Merger With Idera Pharmaceuticals, Inc.
- New Research: Key Drivers of Growth for OFG, Oshkosh, Vishay Precision Group, Endocyte, BioCryst Pharmaceuticals, and Trevena — Factors of Influence, Major Initiatives and Sustained Production
- SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of BioCryst Pharmaceuticals, Inc. - BCRX
- Investor Network: BioCryst Pharmaceuticals, Inc. to Host Earnings Call
-
BioCryst Pharmaceuticals
- BioCryst Announces the Acceptance of Peramivir MAA Filing by the European Medicines Agency
- BioCryst Receives Health Canada Approval for RAPIVAB® for the Treatment of Influenza
- BioCryst to Present at the J.P. Morgan Healthcare Conference
- BioCryst to Present at the Piper Jaffray Healthcare Conference November 30
- BioCryst Reports Third Quarter 2016 Financial Results
- BioCryst Announces Late Breaker Presentation of Galidesivir (BCX4430) Nonclinical Results in Zika Virus Infection at IDWeek 2016
- BioCryst to Announce Third Quarter 2016 Financial Results November 7
